Wednesday, October 7, 2026

Corporate Strategy

2 articles

Coupa Acquires Rossum, Launches Two AI Products, and Hosts Conference on the Same Day

Coupa Acquires Rossum, Launches Two AI Products, and Hosts Conference on the Same Day

Coupa executed a three-part platform blitz on May 12, 2026: acquiring AI document intelligence company Rossum, launching AI products Catalyst and Compose, and holding a major conference simultaneously. The coordinated move signals aggressive competitive repositioning in enterprise spend management. Rivals Basware, Tipalti, Medius, and Tungsten face pressure to respond within 60-90 days.

LM Salvado•
American Express's Cloud Analytics Overhaul to Hit 100% Completion in 2027, Reshaping Competitive Edge

American Express's Cloud Analytics Overhaul to Hit 100% Completion in 2027, Reshaping Competitive Edge

American Express is on track to fully migrate to its third-generation cloud-based data and analytics platform by 2027, a move that has already delivered a 90% reduction in processing time for key marketing and fraud operations. The upgrade underpins the company's ability to deploy generative AI at scale and deepen personalization across its premium card portfolio. Backed by $5 billion in annual technology spend, the platform migration is central to AmEx's strategy to widen its operational moat a

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com